Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

Journal of the Neurological Sciences

Volumn 303, Issue 1-2, 2011, Pages 50-52

  Siger, Małgorzata ^a   Durko, Agnieszka ^a   Nicpan, Agnieszka ^a   Konarska, Maria ^a   Grudziecka, Monika ^a   Selmaj, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Interferon; Multiple sclerosis; Therapy

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DETERIORATION; DISABILITY; DISEASE ACTIVITY; DRUG RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT DURATION;

ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVOUS SYSTEM DISEASES; RECURRENCE;

EID: 79952818945     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.01.016     Document Type: Article

References (13)

1. International Working Group for Treatment Optimization in MS Treatment optimization in multiple sclerosis: report of an international consensus meeting Eur J Neurol 11 2004 43 47
2. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized-double-blind, placebo-controlled trial Neurology 43 1993 655 661
3. L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.M. Herndon, J.R. Richert, and A.M. Salazar Intramuscular interferon ß-1a for disease progression in relapsing multiple sclerosis Ann Neurol 39 1996 285 294 (Pubitemid 26100751)
4. PRISM Study Group Randomized double-blind placebo controlled study of interferon ß-1a in relapsing-remitting multiple sclerosis Lancet 352 1998 1498 1504
5. J. Rio, C. Nos, M. Tintore, N. Tellez, I. Galan, and R. Pelayo Defining the response to interferon-ß in relapsing-remitting multiple sclerosis Ann Neurol 59 2006 344 352 (Pubitemid 43202488)
6. B. Weinstock-Guttman, M. Ramanathan, and R. Zivadinov Interferon-beta treatment for relapsing multiple sclerosis Expert Opin Biol Ther 9 2008 1435 1447
7. X. Wu, P. Dastidar, P. Kuusisto, M. Ukkonen, H. Huhtala, and I. Elovaara Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS Acta Neurol Scand 112 2005 242 247 (Pubitemid 41337072)
8. D.N. Richert, M.C. Zierak, C.N. Bash, B.K. Lewis, H.F. McFarland, and J.A. Frank MRI and clinical activity in MS patients after terminating treatment with interferon beta 1b Mult Scler 6 2000 86 90 (Pubitemid 30218901)
9. P. Rieckmann, K.V. Toyka, C. Bassetti, K. Beer, S. Beer, and U. Buettner Escalating immunotherapy of multiple sclerosis-new aspects and practical application J Neurol 11 2004 1329 1339
10. B.G. Weinshenker, and G.C. Ebers The natural history of multiple sclerosis Can J Neurol 14 1987 255 261 (Pubitemid 17147201)
11. C. Polman, P. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Eng J Med 354 2006 899 910
12. P. Barbero, E. Verdun, M. Bergui, A. Pipieri, M. Clerico, and A. Cucci High-dose, frequently administered interferon beta therapy for relapsing remitting multiple sclerosis must be maintained over long term: the interferon beta dose-reduction study J Neurol Sci 222 2004 13 19 (Pubitemid 38881501)
13. N.D. Richert, M.C. Zierak, C.N. Bash, B.K. Lewis, H.F. McFarland, and J.A. Frank MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b Mult Scler 2 2000 86 90 (Pubitemid 30218901)